GvHD Hub
@gvhd_hub
Followers
3,818
Following
1,029
Media
1,873
Statuses
2,834
A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd
Global
Joined November 2017
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Russian
• 689089 Tweets
#TeachersDay
• 83212 Tweets
#JusticeForChristianah
• 53986 Tweets
Lamborghini
• 48077 Tweets
सर्वपल्ली राधाकृष्णन
• 35424 Tweets
Rebecca Cheptegei
• 28825 Tweets
全世帯支給
• 24859 Tweets
食料品クーポン
• 24384 Tweets
पूर्व राष्ट्रपति
• 22143 Tweets
भारत रत्न
• 21858 Tweets
政策原案
• 20435 Tweets
CERDAS BIJAK Pasti RIDO
• 19735 Tweets
Cara POSITIF Lebih NYAMAN
• 19091 Tweets
#صباح_الاشياء_المشرقه
• 17091 Tweets
物価高対策
• 16647 Tweets
次期衆院選
• 16557 Tweets
Pinned Tweet
Don’t miss a recap of our symposium from
#EBMT2024
, with a presentation on the long-term burden of cGvHD from
@BipinSavani
:
#GvHD
#GvHDsm
1
0
2
What are the current clinical considerations of ECP in chronic
#GvHD
? Click here to read our article summarizing recent advances in understanding pathogenesis and treatment protocols of ECP 👉
#GvHDsm
#MedicalEducation
1
5
80
Click here for the updated recommendations from the
#EBMT
for the prophylaxis and management of
#GvHD
after hematopoietic stem cell transplantation 👉
#GvHDsm
#MedicalEducation
0
11
34
CONGRESS
#EBMT23
| Leo Luznik
@HopkinsMedicine
presents the keynote lecture on PTCy during the opening ceremony of EBMT23. He talks through the the history of the use of PTCy then addresses the current unknowns and future frontiers
#bmtsm
#GvHD
0
12
33
CONGRESS
#Tandem23
| Marie Bleakley
@fredhutch
is speaking during the plenary session on T-cell depletion strategies in acute
#GvHD
. She discusses naïve T-cell depletion, alpha beta TCR T-cells and T-reg enrichment with partial T-cell depletion
#BMTsm
0
6
33
🎉 Excellent symposium delivered yesterday at
#EBMT24
on 30 years of ECP in
#cGvHD
!
Thank you to our distinguished faculty members
@Mohty_EBMT
,
@zina_peric
,
@BipinSavani
, and
@Florent_Malard
for their incredible presentations.
0
8
30
Great 1st GvHD Hub Steering committee meeting at
#EBMT18
. Keep an eye out for updates on the official GvHD Hub launch, coming soon!!
@Mohty_EBMT
#GvHD
1
10
28
CONGRESS
#ASH23
| Robert Zeiser
@UniFreiburg
shares 3-year final safety and efficacy analysis from the phase III REACH study. Improved FFS and higher DOR with RUX vs BAT demonstrates long-term control of cGVHD and good tolerability of RUX in pts ≥12 years of age with SR/D-cGvHD.
0
11
27
Check this out 👇
#GvHD
Post-transplant
#cyclophosphamide
is associated w/ a higher incidence of cardiac events within the first 100 days after allogeneic stem cell transplantation.
#JACCCardioOnc
#CardioOnc
#GVHD
#CVD
#CVRF
#LVEF
#MedTwitter
@RemyDulery
1
40
70
0
16
25
CONGRESS
#ASH23
|
@JeffAuletta
@CIBMTR
shares data comparing PTCy prophylaxis between 8/8 and 7/8 URD HCT in adult pts. Multivariable regression analysis showed no significant differences in either GRFS or OS between recipients of 8/8 and 7/8 URD HCT at 1-3 years post-HCT.
0
11
22
Is ATG in combination with PTCy + CsA an effective treatment option for
#GvHD
prophylaxis in patients who undergo peripheral blood haplo-HCT?
Click here to find out 👉
#GvHDsm
#MedicalEducation
0
10
24
CONGRESS
#Tandem23
| Brian Shaffer
@MSKCancerCenter
discusses PTCy in mismatched URD setting with updates from 15-MMUD & ACCESS. 15-MMUD trial 3-yr OS RIC=69.6% & MAC=62.4%. He also highlights that HLA-C mismatch was associated with increased chronic
#GvHD
in CIBMTR study
#BMTsm
0
16
22
CONGRESS |
#EBMT21
|
@Mohty_EBMT
reported safety & efficacy findings from a 6-month follow-up analysis of REACH2 study ➡️ RUX demonstrated sustained advantage over BAT; longer median DOR, failure-free survival, and event-free survival in RUX arm.
#gvhd
1
6
22
CONGRESS
#ASH21
|
@albertomussetti
@Hhospitalet
compares haplo-HCT and MUD HCT when PTCy is used as prophylaxis in 2155 lymphoma patients. OS was 72% at 1 year & 63% at 2 years. Relapse was 22% at 1 year & 27% at 2 years. All outcomes favoured MUD over haplo
#gvhdsm
#bmtsm
1
8
23
CONGRESS
#Tandem23
|
@OliviaSirpilla
@MayoClinic
describes the creation of anti-E-cadherin chimeric antigen receptor-mesenchymal stromal cells (CAR-MSCs). Treatment with CAR-MSCs in a mouse
#GvHD
model resulted in decreased weight loss, clinical GvHD scores & improved OS
#BMTsm
0
11
20
CONGRESS |
#TCTM21
|
@DrMiguelPerales
,
@sloan_kettering
, introduced the symposium on new perspectives in acute and chronic
#gvhd
management.
#bmtsm
0
13
22
CONGRESS |
#Tandem24
Using the MAGIC model, Yu Akahoshi,
@IcahnMountSinai
, reviews results from an integrated clinical and biomarker grading system for acute
#GvHD
. Akahoshi concludes that the model is superior to the Manhattan model in predicting Day 28 ORR and NRM.
@ASTCT
0
4
21
🚨 NEWS | The
@NCCN
has recommended immunocompromised patients should receive a 3rd dose of the
#COVID19Vaccine
. Those with blood cancers & those who have received allo-HSCT with a history of
#GvHD
are eligible.
#COVID19
#BloodCancerAwarenessMonth
🩸
1
10
21
#GvHDSummit
Olaf Penack, MD: Prophylaxis and treatment of acute
#GvHD
: EBMT-ELN working group recommendations for a standardized practice
@TheEBMT
#gvhdsm
0
11
18
CONGRESS
#ASH22
| Leslie Kean
@DFBC_PedCare
describes real world evidence from pts treated with ABA +CNI/MTX vs ATG or PTCy post-allo-HCT. 7/8 MMUD recipients, OS, ABA+CNI/MTX = 87% vs ATG+CNI/MTX =58%. 8/8 MUD recipients, OS, ABA + CNI/MTX vs ATG+CNI/MTX= 86% vs 70%
#GvHD
#bmtsm
1
10
21
CONGRESS |
#ASH20
|
@Florent_Malard
,
@HopSaintAntoine
reports the successful treatment of intestinal GvHD using a next-gen microbiota biotherapeutic, MaaT013, in a study of 29 patients. ORR 59%, CR 31%, OS 46% at 12 mo.
#gvhdsm
#bmtsm
1
10
20
CONGRESS
#ASH23
| Arnon Nagler
@nagler_EBMT
presents data on relapse incidence post unrelated ASCT in pts treated with PTCy vs conventional prophylaxis (PTCy/TAC or CSA & MMF vs ATG/TAC/MTX). The incidence and severity of aGvHD and cGvHD was similar between both groups, while NRM
1
9
19
CONGRESS|
#COSTEM21
|
@Mohty_EBMT
, highlighted that PtCy is well established GvHD prophylaxis in the haplo setting and showed a comaprison of PtCy vs ATG as GvHD prophylaxis
#GvHD
,
#bmtsm
1
4
20
CONGRESS |
#TCTM21
|
@StephanieLeeMD
,
@fredhutch
, presented a primary analysis of the phase III study REACH3, evaluating ruxolitinib in steroid refractory/dependent cGVHD → higher ORR, longer FFS, and greater symptom improvement for ruxolitinib vs BAT
#gvhdsm
#bmtsm
0
7
20
Weekend revisit:
How can refractoriness be defined in GvHD? When should patients be switched to ruxolitinib? Our first editorial theme article on SR-GvHD explores these questions.
@Mohty_EBMT
@StevenPavletic
Click here to read 👉 .
0
5
18
Professor Mohamad Mohty | Highlights of
#GvHD
at
#ASH18
:
@Mohty_EBMT
@ASH_hematology
#gvhdsm
#bmtsm
0
10
19
The
@gvhd_hub
is live now! Watch our chair, Mohamad Mohty introducing the website here:
@Mohty_EBMT
#GvHD
#gvhdsm
#bmtsm
#EHA23
#hematology
0
9
19
CONGRESS |
#IACH23
|
@Mohty_EBMT
,
@Sorbonne_Univ_
summarizes the major challenges in the progress of therapies for cGvHD including choosing the right treatment for the right patient, how to rationally choose drug combinations, and development of biomarkers for clinical use
#GVHD
0
7
19
CONGRESS
#ASH22
|
@Mohty_EBMT
@Sorbonne_Univ_
presents data on MaaT013 in the EAP. N = 81 pts with SR/SD GI-aGvHD. D28 GI ORR = 56% & OS was 51% at 6 months. aGvHD response was improved in 31 patients previously treated with Ruxo as 2nd line & MaaT013 as 3rd line
#GvHD
#BMTSM
1
8
18
CONGRESS |
#Tandem24
H. Rangarajan,
@hmgcoa2
,
@nationwidekids
, presents data supporting the use of vedolizumab in children and young adults with lower GI SR-aGvHD. Intestinal response at Day 28, ORR was 74% and mean baseline steroid dose decreased from 1.5 to 0.79mg/kg. ORR at
0
4
18
CONGRESS |
#EHA2021
| Leo Luznik,
@HopkinsMedicine
focused his talk on PTCy in-vivo T-cell depletion ➡️ limits both acute and chronic
#GvHD
, effective across donor types (MSD, MUD, haplos and mMUD), caution extrapolating PB data, addition of pre-BMT ATG
#gvhdsm
#BMTsm
2
4
18
CONGRESS
#Tandem23
| Pooja Khandelwal
@BmtCincy
@CincyChildrens
presents an abstract on Vit A for the prevention of acute and chronic
#GvHD
in children and young adults. High-dose Vit A prior to HSCT was associated with reduced acute GI GvHD and chronic GvHD vs placebo.
#BMTsm
1
10
17
CONGRESS |
#EBMT21
| A. Pérez-Martínez,
@HospitalULaPaz
evaluated the safety of a single infusion of CD45RA- memory T cells containing SARSCoV2 specific T cells from a
#COVID19
convalescent donor as adoptive cell therapy against moderate/severe cases of COVID-19
#SESCOVID19
#GvHD
0
4
15
CONGRESS |
#Tandem24
@DrZackDeFilipp
summarizes data from the AGAVE-201 study, which met the primary endpoint. Dose levels of axatilimab were assessed in pts with R/R chronic
#GvHD
. Findings from the 0.3mg/kg Q2W dose were presented; by cycle 7 ORR was 74%.
@MGHCancerCenter
0
4
17
During the ELN WP14 Transplantation meeting, Ernst Holler,
@presse_ukr
, presented a keynote lecture describing how microbiota disruption prior to transplantation predicts mortality, with low diversity resulting in worse prognosis
#GvHDsm
#bmtsm
0
9
15
Thank you
@TheEBMT
for all the interesting content at the
#GvHDSummit
. Read the highlights here:
@GrzegorzBasak
,
@DrMvandenBrink
,
@zina_peric
,
@StevenPavletic
,
@StLouis_Larib
,
#gvhdsm
#bmtsm
#GvHD
0
7
16
Congress
#EBMT2022
|
@DrCCutler
,
@DanaFarberNews
, presents a poster on the 2-year safety results from the phase II ROCKstar trial that investigates belumosudil for patients with chronic
#GvHD
.
#bmtsm
1
5
16
Join our live online symposium on the role extracorporeal photopheresis (
#ECP
) in the management of
#GvHD
.
📅 Nov 29
🕔 17:00–19:00 CET
Submitted for CME accreditation
#GvHDtreatment
#stemcelltransplant
#bonemarrowtransplant
#leukapheresis
0
4
15
CONGRESS
#ASH23
|
@NikolaSpyrouMD
@IcahnMountSinai
discusses the possibility of a Day 14 endpoint for clinical trials in aGvHD, comparing data from three predictive models; D28 ORR, D14 Mount Sinai, and D14 MAGIC. Results showed the MAGIC integrated model to be the most accurate
0
3
10
CONGRESS
#ASCO19
| Dr. Uday R Popat provides result from a phase II study on post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen.🧬📈🧬
@MDAndersonNews
#GvHD
#gvhdsm
#bmtsm
1
8
16
What are the latest developments in the prevention and treatment of acute
#GvHD
? Read our review summary here 👉 .
#GvHDsm
#MedicalEducation
0
2
16
“There is a lot of excitement in the field of
#GvHD
, which is why we felt there was a need for an educational hub in order to share information and latest advances to help the transplant community to better manage patients with GvHD” Professor Mohamad Mohty
@Mohty_EBMT
#bmtsm
0
6
16
CONGRESS
#EBMT23
|
@StevenPavletic
@theNCI
describes the diagnosis and risk assessment of patients with chronic
#GvHD
in this educational session. He discusses specific organ manifestations such as lung and liver and also factors that affect prognostication such as frailty
#bmtsm
1
4
16
CONGRESS
#ASH23
| Yu Akahoshi
@IcahnMountSinai
provides insights into flares of aGvHD using data from the MAGIC study. Flares of
#GvHD
symptoms following CR/VGPR responses still occur in over 1/5 of patients and are associated with 5x increase in NRM. Ann Arbor scores were shown
0
5
12
CONGRESS
#ASH22
|
@VijayaRBhatt1
@UNMC_IM
discusses the results of phase II trial of ruxolitinib for SR sclerotic cGvHD. N=47. Overall cGVHD partial responses were seen in 47%; other responses included SD (13%), mixed responses/progression (27%) & missing (13%).
#GvHD
#BMTSM
0
9
15
Check out our article summarizing data from the MAGIC analysis evaluating the use of biomarkers to predict flares of acute
#GvHD
here 👉
@IcahnMountSinai
#GvHDsm
#MedicalEducation
1
6
13
CONGRESS
#EBMT22
|
@StephanieLeeMD
@fredhutch
discusses various risk stratification models for chronic
#GvHD
. None are ready for clinical use: the hunt for applicable risk stratification systems is still ongoing.
#bmtsm
#gvhdsm
0
5
15
How can refractoriness be defined in GvHD? When should patients be switched to ruxolitinib? Our first editorial theme article on SR-GvHD explores these questions.
@Mohty_EBMT
@StevenPavletic
Click here to read 👉 .
0
4
14
CONGRESS |
#EBMT20Virtual
|
@razan_mohty
,
@AUB_Lebanon
, presents data from a study which concluded that early initiation of antibiotics, without prior prophylaxis, before graft infusion is associated with a significantly higher risk of Grade 3-4 aGvHD.
#gvhdsm
#bmtsm
1
9
15
#EHA23
A brilliant overview on JAK 2 inhibition in the treatment of GvHD was presented by Nikolas von Bubnoff
#bmtsm
#GvHD
#hematology
@EHA_Hematology
0
10
14
Congress|
#SOHO2021
|
@dancourielBMT
,
@HuntsmanCancer
, discusses the management of chronic
#gvhd
. He focus on newer strategies such as ibrutinib and belumosudil which are FDA approved.
1
6
15
CONGRESS
#ASH23
|
@DTzachanis
,
@UCSDHealth
, presents findings of a prospective RCT evaluating calcineurin-free
#GvHD
prophylaxis with PTCy & abatacept vs the SOC with tacrolimus & methotrexate. The primary endpoint was met: moderate & severe cGvHD were 0% with abatacept vs 65.8%
1
5
12
#EBMT19
@MSanchezEscamil
presents data showing EASIX score predicts grade 1-4 and 2-4 acute
#GvHD
, and a lower EASIX-GvHD score may predict day 28 complete responses to first line therapy
#bmtsm
0
8
14
Great to see
#GvHD
presentations at the
#IACH19
meeting 😃 Here are slides shared by
@DrMCanales
on the treatment of acute GvHD (aGvHD), as presented by Dr Ernst Holler. Treatment options include: 1⃣ Corticosteroids (pros and cons) 2⃣ Mesenchymal stem cells 3⃣ Ruxolitinib
0
4
14
Nelli Bejanyan and colleagues: Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic graft-versus-host disease
@BloodAdvances
#GvHD
#gvhdsm
#bmtsm
0
7
14
The GvHD Hub will be attending the
#EHA23
Annual Congress in Stockholm covering all the key talks on graft-versus-host disease.
#GvHD
#bmtsm
#EHA18
@EHA_Hematology
@sci_ed_support
@Mohty_EBMT
0
6
14
CONGRESS
#ASH23
|
@DrAlinaMarkova
@MSKCancerCenter
@MSK_DeptOfMed
shares results from a phase II clinical trial of topical ruxolitinib for cutaneous cGvHD. Ruxolitinib 1.5% cream was shown to be a safe and effective treatment for cutaneous nonsclerotic and superficially sclerotic
0
7
14
CONGRESS
#ASH22
|
@sghmd
@umnmedschool
presents the LBA on a phase III trial BMTCTN1703 of PTCy/Tac/MMF vs Tac/MTX for
#GvHD
prophylaxis. N=431. PTCy grp had a sig lower HR of GRFS vs Tac/MTX (HR 0.641). The adjusted 1-yr GRFS rate =52.7% for the PTCy arm & 34.9% for the ctrl arm
2
10
11
#GvHDSummit
Olaf Penack, MD: Prophylaxis and treatment of chronic
#GvHD
: EBMT-ELN working group recommendations for a standardized practice
@TheEBMT
#gvhdsm
0
8
14
CONGRESS |
#ASH20
|
@DrCCutler
,
@DanaFarber
, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for cGvHD, which met its primary endpoint of ORR (> 70% for both doses) and was well tolerated. PK and PD data expected in early 2021
#gvhdsm
#gvhd
1
4
13
CONGRESS
#ASH23
| Beatriz Merchán Muñoz
@hospitalclinic
, shares data on the impact of PTCy-based prophylaxis on immune reconstitution and infectious complication in adult pts following peripheral blood allo-HCT. Pts receiving PTCy-based prophylaxis were shown to relevant
0
5
14
CONGRESS |
#EHA2022
| Federico Stella,
@LaStatale
presents results from a multi-center NEUTRODIET study comparing protective diet and non-restrictive diet.
- No difference in infection rates, death or aGvHD incidence
- Higher GI rates with protective diet
#gvhd
1
7
14
Can a higher CD34+ cell dose, in donor grafts, impact patient outcomes after haplo-PBSCT with PTCy treatment? Find out more in our article summarizing data from a retrospective single-center study 👉 .
#GvHDsm
#MedicalEducation
0
4
14
CONGRESS
#EBMT23
|
@Mohty_EBMT
discusses the treatment of patients with steroid refractory chronic GvHD. Rux has demonstrated superior efficacy against BAT but doesn't solve the whole problem. Belumosudil may may be an attractive option in the advanced setting
#bmtsm
#GvHD
0
8
14
CONGRESS
#Tandem23
| Yiwen Li
@WinshipAtEmory
presents data on vasoactive intestinal peptide (VIP) & its role in suppressing
#GvHD
. VIP KO mice have >GvHD than WT mice post BMT. Local production of VIP in the gut shifts the microbiome towards tolerogenic bacterial species.
#BMTsm
1
7
12
CONGRESS |
#TCTM20
| Hrishikesh Srinagesh,
@Hsrinagesh
, presents the MAGIC algorithm probability (MAP) as a way to assess response in aGvHD. The MAP is the first laboratory test that can more accurately predict clinical response after 28 days of treatment
#gvhd
1
6
12